Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Enasidenib in Combination with Venetoclax in IDH2 -Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial

Steven M Chan, Charina Cameron, Severine Cathelin, Vikas Gupta, Dawn Maze, Mark D. Minden, Tracy Murphy, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Caroline J McNamara

Blood (2021) 138 (Supplement 1): 1263.

https://doi.org/10.1182/blood-2021-153660

Published: 2021

Journal Articles

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Blood (2020) 136 (Supplement 1): 52–53.

https://doi.org/10.1182/blood-2020-141790

Published: 2020

Journal Articles

Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS

Tracy Murphy, MDFRCP,FRCPath, Brian Leber, MD, Mark R Bray, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dina Khalaf, BSc, MSc, MD, Dawn Maze, MDFRCPC,MSc, Caroline J McNamara, MBBS, Aaron D Schimmer, MD PhD, Andre C. Schuh, Hassan Sibai, MBBS, Graham Fletcher, Debbie Valiquette, Kylie Martin, BSc, RN, BSN, Mark D. Minden, Karen W.L. Yee, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-138822

Published: 2020

Journal Articles

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation

Muhned Alhumaid, MD, Georgina S. Daher-Reyes, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Anne Tierens, MD PhD, Caroline J McNamara, MBBS, Dawn Maze, MDFRCPC,MSc, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Karen W.L. Yee, MD, Mark D. Minden, Steven M Chan, MD PhD, Tracy Murphy, MDFRCP,FRCPath, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 8–9.

https://doi.org/10.1182/blood-2020-138862

Published: 2020

Journal Articles

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Claire Andrews, Taylor Young, Eshetu G Atenafu, M.Sc., P.Stat, Sarit E Assouline, MD MSc, Joseph M Brandwein, MD, Steven M Chan, MD PhD, Signy Chow, MD FRCP(C), Dina Khalaf, BSc, MSc, MD, Vikas Gupta, MD FRCP, FRCPath, Dennis Dong Hwan Kim, MD, Dawn Maze, MDFRCPC,MSc, Mark D. Minden, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, David Sanford, MD, Aaron D Schimmer, MD PhD, Andre C. Schuh, Karen W.L. Yee, MD, Hassan Sibai, MBBS

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-142990

Published: 2020

Journal Articles

Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-138943

Published: 2020

Journal Articles

Geographical Distance from Quaternary Treatment Center Does Not Impact Choice of Upfront Therapy, Clinical Trial Participation and Outcomes in Patients with Newly Diagnosed AML

Samantha A Hershenfeld, MD, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dawn Maze, MDFRCPC,MSc, Caroline J McNamara, MBBS, Mark D. Minden, Tracy Murphy, MDFRCP,FRCPath, Andre C. Schuh, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Aaron D Schimmer, MD PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-134645

Published: 2020

Journal Articles

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

Muhned Alhumaid, MD, Georgina S Daher-Reyes, MD, Wilson Lam, MD, Arjun Law, MDDM, Tracy Murphy, MDFRCP,FRCPath, Caroline J McNamara, MBBS, Gil Yerushalmi, Aaron D Schimmer, MD PhD, Andre C. Schuh, MD, Dawn Maze, MDFRCPC,MSc, Eshetu G Atenafu, M.Sc., P.Stat, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Hassan Sibai, MBBS

Blood (2019) 134 (Supplement_1): 2609.

https://doi.org/10.1182/blood-2019-125449

Published: 2019

Journal Articles

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free Pediatric-Inspired ALL Regimen with Imatinib

Ruiqi Chen, MSc, Xing Liu, PharmD, Solaf Kanfar, MD, Dawn Maze, MDFRCPC,MSc, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Aaron D Schimmer, MD PhD, Andre C. Schuh, MD, Caroline J McNamara, MBBS, Tracy Murphy, MDFRCP,FRCPath, Anna Xu, Umberto Falcone, MD, Jack Seki, PharmD, Hassan Sibai, MBBS

Blood (2019) 134 (Supplement_1): 1303.

https://doi.org/10.1182/blood-2019-124117

Published: 2019

Journal Articles

High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1424.

https://doi.org/10.1182/blood-2019-122890

Published: 2019

Journal Articles

HSCs Fated to Progress to Blast Phase Can be Detected in Myelofibrosis Patients Several Years Prior to Leukemic Transformation

Jenny M. Ho, MD, Jessie J.F. Medeiros, BSc, Michelle Chan-Seng-Yue, Lauren Hummel, BSc, Andrea Arruda, Amanda Mitchell, PhD, Caroline J McNamara, MBBS, James A Kennedy, MD PhD, Anne Tierens, MD PhD, Dawn Maze, MDFRCPC,MSc, Hubert Tsui, MD PhD, Mark D. Minden, MD PhD, Vikas Gupta, MD FRCP, FRCPath, John E. Dick, PhD

Blood (2019) 134 (Supplement_1): 1676.

https://doi.org/10.1182/blood-2019-130923

Published: 2019

Journal Articles

Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia

Blood (2019) 134 (Supplement_1): 5725.

https://doi.org/10.1182/blood-2019-129078

Published: 2019

Journal Articles

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 3317.

https://doi.org/10.1182/blood-2019-125780

Published: 2019

Journal Articles

Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML

Robert Puckrin, MD, Eshetu G Atenafu, M.Sc., P.Stat, Jaime Claudio, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Dawn Maze, MDFRCPC,MSc, Caroline J McNamara, MBBS, Mark D. Minden, MD PhD, Andre Schuh, Tracy Murphy, MDFRCP,FRCPath, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Aaron D Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 436.

https://doi.org/10.1182/blood-2018-99-113090

Published: 2018

Journal Articles

AML-Fated Clones Arise in Stem and Progenitor Cells in Myelofibrosis Patients Several Years Prior to AML Diagnosis

Jenny M. Ho, MD, Jessie James Franco Medeiros, BSc, Michelle Chan-Seng-Yue, Lauren Hummel, BSc, Andrea Arruda, Amanda Mitchell, PhD, Caroline J McNamara, MBBS, James Kennedy, MD PhD, Anne Tierens, MD PhD, Hubert Tsui, MD PhD, Mark D. Minden, MD PhD, Vikas Gupta, MD FRCP, FRCPath, John E. Dick, PhD

Blood (2018) 132 (Supplement 1): 4321.

https://doi.org/10.1182/blood-2018-99-118889

Published: 2018

Journal Articles

Anticoagulation Prophylaxis with Weight-Adjusted Enoxaparin Reduces Rates of Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy

Hassan Sibai, MBBS, Ruiqi Chen, Xing Liu, Aaron D Schimmer, MD PhD, Andre Schuh, Arjun Law, MDDM, Caroline J McNamara, MBBS, Dawn Maze, MD FRCPC, MSc, Karen W.L. Yee, MD, Mark D. Minden, MD PhD, Steven M Chan, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Tracy Murphy, MD FRCP, FRCPath, Umberto Falcone, MD, Naoko Sakurai, Joseph M. Brandwein, MD FRCPC, Jack Seki, PharmD

Blood (2018) 132 (Supplement 1): 3974.

https://doi.org/10.1182/blood-2018-99-119984

Published: 2018

Journal Articles

Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations

Tracy Murphy, MDFRCP,FRCPath, Jinfeng Zou, PhD, Georgina S Daher-Reyes, MD, Vikas Gupta, MD FRCP, FRCPath, Caroline J McNamara, MBBS, Mark D. Minden, MD PhD, Aaron D Schimmer, MD PhD, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Tracy L. Stockley, PhD FCCMG, FACMG, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Dawn Maze, MDFRCPC,MSc, Scott Bratman, MD PhD, Andre Schuh, Steven M Chan, MD PhD

Blood (2018) 132 (Supplement 1): 992.

https://doi.org/10.1182/blood-2018-99-115518

Published: 2018

Journal Articles

Impact of Genetic Profile on Clinical Outcomes in Adults ≥60 with AML: The Princess Margaret Cancer Centre Experience

Georgina S Daher-Reyes, MD, Caroline J McNamara, MBBS, Manjula Maganti, MSc, Tracy L. Stockley, PhD FCCMG, FACMG, Jose Mario Capo-Chichi, PhD FACMG, Reem Abdulrahman Alkharras, Andrea Arruda, Jaime Claudio, Steven M Chan, MD PhD, Aaron D Schimmer, MD PhD, Mark D. Minden, MD PhD, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Vikas Gupta, MD FRCP, FRCPath, Suzanne Kamel-Reid, BA, MA, PhD FACMG, Dawn Maze, MD FRCPC, MSc, Andre Schuh

Blood (2018) 132 (Supplement 1): 2666.

https://doi.org/10.1182/blood-2018-99-118938

Published: 2018

NARROW

Enasidenib in Combination with Venetoclax in IDH2 -Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial

Role of Allogeneic Hematopoietic Cell Transplant in Patients with Myelofibrosis in the JAK Inhibitor Era

Preliminary Results from a Phase 1 Study of Cfi-400495, a PLK4 Inhibitor, in Patients with Acute Myeloid Leukemia and High Risk MDS

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Harboring DNMT3A/TET2/ASXL1 Mutation

CPX351 Has Short Remission Duration but Is an Effective Bridge to Allogeneic Transplant in High Risk AML: Results from Canadian Real-World Multi-Centre Study

Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA

Geographical Distance from Quaternary Treatment Center Does Not Impact Choice of Upfront Therapy, Clinical Trial Participation and Outcomes in Patients with Newly Diagnosed AML

Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML): Princess Margaret Cancer Centre Experience

Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free Pediatric-Inspired ALL Regimen with Imatinib

High Interpatient Variability in Molecular MRD Response to Consolidation Chemotherapy in Acute Myeloid Leukemia

HSCs Fated to Progress to Blast Phase Can be Detected in Myelofibrosis Patients Several Years Prior to Leukemic Transformation

Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Molecular Residual Disease Monitoring Provides Insufficient Lead-Time to Prevent Morphologic Relapse in the Majority of Patients with Core-Binding Factor AML

AML-Fated Clones Arise in Stem and Progenitor Cells in Myelofibrosis Patients Several Years Prior to AML Diagnosis

Anticoagulation Prophylaxis with Weight-Adjusted Enoxaparin Reduces Rates of Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia Receiving Asparaginase-Based Intensification Therapy

Delayed Hematologic Recovery in AML Patients after Induction Chemotherapy Is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations

Impact of Genetic Profile on Clinical Outcomes in Adults ≥60 with AML: The Princess Margaret Cancer Centre Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only